RLRobert B. Lorsbach

Robert B. Lorsbach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert B. Lorsbach has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Moore

    From the Department of Pathology, St Jude Children's Research Hospital, Memphis, TN

    2 shared publications
  • Dominic Shay-Seymore

    From the Departments of Pathology and Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN; the Department of Pathology, Carolinas Medical Center, Charlotte, NC; and the Department of Pathology, Baystate Medical Center, Springfield, MA

    1 shared publication
  • Frederick G. Behm

    From the Departments of Pathology and Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN; the Department of Pathology, Carolinas Medical Center, Charlotte, NC; and the Department of Pathology, Baystate Medical Center, Springfield, MA

    1 shared publication
  • G S Pinkus

    1 shared publication
  • James R. Downing

    From the Department of Pathology, St Jude Children's Research Hospital, Memphis, TN

    1 shared publication
  • John T. Sandlund

    From the Departments of Pathology and Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN; the Department of Pathology, Carolinas Medical Center, Charlotte, NC; and the Department of Pathology, Baystate Medical Center, Springfield, MA

    1 shared publication

Latest Publications

  • Megakaryoblastic Disorders in Children

    by Robert B. Lorsbach

    Acute leukemia is the most common neoplasm in children, of which approximately one fourth of cases are acute myeloid leukemia. To a large extent, the clinicopathologic spectrum of acute myeloid leukemia seen in the pediatric age group is similar to that in adults. However, megakaryoblastic proliferations, including transient myeloproliferative disorder and acute megakaryoblastic leukemia, occur exclusively or predominantly in children. Although the clinical and pathologic features of these disorders have been well characterized, until recently their pathogenetic mechanisms have remained poorly understood. Recent advances have provided important insight into the pathogenesis of these disorders, and they provide a molecular basis for a clinically meaningful classification of primary megakaryoblastic disorders in the pediatric age group.


  • Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression

    by Robert B. Lorsbach, Jennifer Moore, Sonny O. Ang, Weili Sun, Noel Lenny, James R. Downing

    The Runx1/core binding factor-β (CBFβ) transcriptional complex is required for the establishment of hematopoiesis during development. Despite its critical role during development, a detailed analysis of Runx1 expression within specific lineages and developmental stages of the adult hematopoietic system is lacking. To address this, we have developed a Runx1—green fluorescent protein (GFP) knock-in mouse. We show that Runx1 is expressed in several hematopoietic lineages, including myeloid, B-lymphoid, and T-lymphoid cells. By contrast, Runx1 is weakly expressed in early erythroid cells, and its expression is rapidly extinguished during later stages of erythropoiesis. Runx1 expression is induced during early B-cell development and is expressed at a uniform level during all subsequent stages of B-cell development. Within the thymus, Runx1 is expressed at the highest level in CD4-CD8- double-negative thymocytes. In peripheral T cells, Runx1 is differentially expressed, with CD4+ T cells expressing 2- to 3-fold higher levels of Runx1 than CD8+ cells. Taken together, these findings indicate that although widely expressed in the hematopoietic system, the expression of Runx1 is regulated in a cell type— and maturation stage—specific manner. In addition, the Runx1-IRES-GFP knock-in mouse strain should prove valuable for investigation of Runx1 function in adult hematopoiesis.


  • Open Access

    Clinicopathologic analysis of follicular lymphoma occurring in children

    by Robert B. Lorsbach, Dominic Shay-Seymore, Jennifer Moore, Peter M. Banks, Robert P. Hasserjian, John T. Sandlund, Frederick G. Behm

    Follicular lymphoma is a rare lymphoid malignancy in pediatric patients and consequently remains poorly characterized, particularly with respect to its immunophenotype and molecular pathogenesis. A total of 23 pediatric patients with follicular lymphoma were identified, with a median age of 11 years and a male-to-female ratio of 2.3:1. Of the 19 patients for whom presenting clinical features were available, 15 patients had stage I, 1 had stage II, and 3 had stage III or IV disease. All tumors had a follicular architecture, and 74% of cases had grade 2 or 3 histologic features. All patients expressed CD20 and bcl-6, and 80% were positive for CD10. Bcl-2 expression was detected in only 5 of 16 cases. Consistent with this finding, bcl-2 gene rearrangements were detected in only 2 of 16 cases by polymerase chain reaction. These patients were treated primarily with cyclophosphamide, doxorubicin, vincristine, and prednisone–based chemotherapy; 4 patients also received involved-field irradiation. Of the 13 patients with available clinical follow-up, all but 2 achieved durable clinical remission. Importantly, all 4 patients with tumors diffusely positive for bcl-2 either presented with stage III/IV disease or had disease refractory to therapy, whereas patients with bcl-2–negative tumors uniformly had stage I disease, achieved complete remission, and experienced no relapses. These findings indicate that, in contrast to adult follicular lymphomas, dysregulated bcl-2 expression does not play a significant pathogenetic role in most pediatric follicular lymphomas. However, bcl-2 expression in pediatric follicular lymphoma identifies a subset of patients in whom disease is often disseminated at clinical presentation and is more refractory to combination chemotherapy.


    • 1 December 1999
      • Vol. 12  (12) , 1186-91

    Relapse of acute myelogenous leukemia as a cerebellar myeloblastoma showing megakaryoblastic differentiation.

    by R B Lorsbach, R D Folkerth, G S Pinkus

    Myeloblastomas (granulocytic sarcomas) occurring within the central nervous system (CNS) are extremely rare lesions that may develop in patients with acute or chronic myeloproliferative disorders. The majority of such lesions involve brain or spinal cord by contiguous spread from meningeal or bony sites, rather than originating within the CNS parenchyma. We describe a patient with acute myelogenous leukemia in remission, who developed a purely intraparenchymal cerebellar myeloblastoma with megakaryocytic differentiation. The neoplastic cells expressed the megakaryocytic markers factor VIII-related antigen and platelet glycoprotein-IIIa (CD61), and showed ultrastructural features that were indicative of megakaryocytic differentiation. Clinically, myeloblastomas of the CNS invoke a broad differential diagnosis that includes abscess, hemorrhage, and metastatic neoplasms because of their intraparenchymal location and radiologic features. Although they are rare, myeloblastomas should be included in the histopathologic differential diagnosis of a poorly differentiated neoplasm occurring within the CNS, particularly in a patient with a history of myeloproliferative or myelodysplastic disease.